Replies to post #119142 on Biotech Values

[DewDiligence]

What REGN ultimately might need is a trial with "as-needed" Lucentis vs. "as-needed" trap. I suspect that the trap would require significantly fewer injections over a multi-year period.

Exactly right, IMO. I’ve been saying for years that REGN’s AMD program was aiming too low, and I think this is now clear.

[DewDiligence]

Maybe REGN will end up running a head-to-head trial against MP0112 in due course :- )